Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.
Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois.
JAMA Otolaryngol Head Neck Surg. 2023 Jan 1;149(1):79-86. doi: 10.1001/jamaoto.2022.3781.
Tall cell morphology (TCM) is a rare and aggressive variant of papillary thyroid carcinoma (PTC) that has been associated with poor outcomes; however, the risk factors for worse survival are not well characterized.
To identify prognostic factors associated with cancer recurrence and death in patients with PTC-TCM.
DESIGN, SETTING, AND PARTICIPANTS: All patients treated for PTC-TCM at a single tertiary-level academic health care institution from January 1, 1997, through July 31, 2018, were included. Tall cell variant (TCV) was defined as PTC with TCM of 30% or more; and tall cell features (TCF) was defined as PTC with TCM of less than 30%. Patients with other coexisting histologic findings and/or nonsurgical management were excluded. Clinicopathologic features associated with worse outcomes were identified using Kaplan-Meier and Cox proportional-hazards model. Data were analyzed from March 1, 2018, to August 15, 2018.
Locoregional recurrence-free survival (LRRFS), distant recurrence-free survival (DRFS), and overall survival (OS) after surgery.
A total of 365 patients (median [range] age, 51.8 [15.9-91.6] years; 242 [66.3%] female) with PTC-TCM (TCV, 32%; TCF, 68%) were evaluable. Total thyroidectomy was performed in 336 (92%) patients; 19 (5.2%) received radiotherapy; and 15 (4.1%) received radioactive iodine. Clinical features were pT3 or T4, 65%; node-positive, 53%; and positive surgical margins, 24%. LRRFS at 1-, 3-, 5-, and 10-year was 95%, 87%, 82%, and 73%, respectively. On multivariable analysis, male sex and age were not independent predictors of inferior 5-year LRRFS, whereas positive surgical margins (HR, 3.5; 95% CI, 2.0-6.3), positive lymph nodes (HR, 2.8; 95% CI, 1.4-5.8), and primary tumor size of 3 cm or more (HR, 3.3; 95% CI, 1.4-7.8) were strongly associated with worse LRRFS. Age 55 years or older (HR, 3.2; 95% CI, 1.5-7.0), male sex (HR 4.5; 95% CI, 2.1-10.0), positive surgical margins (HR, 2.7; 95% CI, 1.2-6.0), nodal positivity (HR, 3.1; 95% CI, 1.3-7.7), tumor diameter of 1.5 cm or more (HR, 20.6; 95% CI, 2.8-152.1), and TCV vs TCF (HR, 3.1; 95% CI, 1.5-6.7) were associated with worse DRFS. Male sex (HR, 3.1; 95% 1.4-6.8) and tumor diameter of 1.5 cm or more (HR, 2.8; 95% CI, 1.0-7.4) were associated with worse OS. A findings-based nomogram was constructed to predict 10-year LRRFS (C index, 0.8).
This retrospective cohort study found that in patients with PTC-TCM, positive surgical margins, node positive disease, and tumor size of 3 cm or more were risk factors for worse LRRFS. Intensified locoregional therapy, including adjuvant radiation, may be considered for treating these patients.
高细胞形态(TCM)是甲状腺乳头状癌(PTC)的一种罕见且侵袭性的变体,与不良结局相关;然而,与生存较差相关的危险因素尚未得到很好的描述。
确定与 PTC-TCM 患者癌症复发和死亡相关的预后因素。
设计、地点和参与者:所有在单一三级学术医疗保健机构接受 PTC-TCM 治疗的患者均纳入本研究,纳入时间为 1997 年 1 月 1 日至 2018 年 7 月 31 日。高细胞变体(TCV)定义为 TCM 占比 30%或以上的 PTC;高细胞特征(TCF)定义为 TCM 占比低于 30%的 PTC。排除了其他共存组织学发现和/或非手术治疗的患者。使用 Kaplan-Meier 和 Cox 比例风险模型确定与不良结局相关的临床病理特征。数据分析于 2018 年 3 月 1 日至 2018 年 8 月 15 日进行。
手术治疗后的局部区域无复发生存率(LRRFS)、远处无复发生存率(DRFS)和总体生存率(OS)。
共纳入 365 例(中位[范围]年龄,51.8[15.9-91.6]岁;242[66.3%]为女性)PTC-TCM(TCV,32%;TCF,68%)患者,其中 336 例(92%)患者接受了全甲状腺切除术;19 例(5.2%)接受了放疗;15 例(4.1%)接受了放射性碘治疗。临床特征为 pT3 或 T4,占 65%;淋巴结阳性,占 53%;切缘阳性,占 24%。1、3、5 和 10 年的 LRRFS 分别为 95%、87%、82%和 73%。多变量分析显示,男性和年龄并不是 5 年 LRRFS 较差的独立预测因素,而阳性切缘(HR,3.5;95%CI,2.0-6.3)、阳性淋巴结(HR,2.8;95%CI,1.4-5.8)和原发肿瘤大小为 3cm 或更大(HR,3.3;95%CI,1.4-7.8)与较差的 LRRFS 密切相关。年龄 55 岁或以上(HR,3.2;95%CI,1.5-7.0)、男性(HR,4.5;95%CI,2.1-10.0)、阳性切缘(HR,2.7;95%CI,1.2-6.0)、淋巴结阳性(HR,3.1;95%CI,1.3-7.7)、肿瘤直径为 1.5cm 或更大(HR,20.6;95%CI,2.8-152.1)以及 TCV 与 TCF(HR,3.1;95%CI,1.5-6.7)与 DRFS 较差相关。男性(HR,3.1;95%CI,1.4-6.8)和肿瘤直径为 1.5cm 或更大(HR,2.8;95%CI,1.0-7.4)与 OS 较差相关。构建了一个基于发现的列线图来预测 10 年 LRRFS(C 指数,0.8)。
本回顾性队列研究发现,在 PTC-TCM 患者中,阳性切缘、淋巴结阳性疾病和肿瘤大小为 3cm 或更大是 LRRFS 较差的危险因素。可能需要考虑强化局部区域治疗,包括辅助放疗,以治疗这些患者。